MX2015005963A - GLUTAMINASE HETEROCICLIC INHIBITORS. - Google Patents

GLUTAMINASE HETEROCICLIC INHIBITORS.

Info

Publication number
MX2015005963A
MX2015005963A MX2015005963A MX2015005963A MX2015005963A MX 2015005963 A MX2015005963 A MX 2015005963A MX 2015005963 A MX2015005963 A MX 2015005963A MX 2015005963 A MX2015005963 A MX 2015005963A MX 2015005963 A MX2015005963 A MX 2015005963A
Authority
MX
Mexico
Prior art keywords
heterocyclic
glutaminase inhibitors
glutaminase
inhibitors
compounds
Prior art date
Application number
MX2015005963A
Other languages
English (en)
Inventor
Lijing Chen
Bindu Goyal
Guy Laidig
Timothy Friend Stanton
Eric Brian Sjogren
Li Jim
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261727195P priority Critical
Priority to US201361824434P priority
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Priority to PCT/US2013/070277 priority patent/WO2014078645A1/en
Publication of MX2015005963A publication Critical patent/MX2015005963A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

En la presente se describen compuestos heterocíclicos que contienen anillos de tiadiazol y/o piridazina, así como preparaciones farmacéuticas de los mismos. Los compuestos en la presente se hacen además conocidos por ser útiles como inhibidores de glutaminasa con usos potenciales en el tratamiento de cáncer, enfermedades inmunológicas y neurológicas.Heterocyclic compounds containing thiadiazole and / or pyridazine rings, as well as pharmaceutical preparations thereof, are described herein. The compounds herein are further known to be useful as glutaminase inhibitors with potential uses in the treatment of cancer, immunological and neurological diseases.
MX2015005963A 2012-11-16 2013-11-15 GLUTAMINASE HETEROCICLIC INHIBITORS. MX2015005963A (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201261727195P true 2012-11-16 2012-11-16
US201361824434P true 2013-05-17 2013-05-17
PCT/US2013/070277 WO2014078645A1 (en) 2012-11-16 2013-11-15 Heterocyclic glutaminase inhibitors

Publications (1)

Publication Number Publication Date
MX2015005963A true MX2015005963A (es) 2015-09-16

Family

ID=50731715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005963A MX2015005963A (es) 2012-11-16 2013-11-15 GLUTAMINASE HETEROCICLIC INHIBITORS.

Country Status (15)

Country Link
US (1) US10793535B2 (es)
EP (1) EP2920168A4 (es)
JP (1) JP6275153B2 (es)
KR (1) KR20150085053A (es)
CN (1) CN105051041B (es)
AU (1) AU2013344560B2 (es)
BR (1) BR112015010955A2 (es)
CA (1) CA2891667A1 (es)
EA (1) EA029707B1 (es)
HK (1) HK1215023A1 (es)
IL (1) IL238787D0 (es)
MX (1) MX2015005963A (es)
SG (1) SG11201503720SA (es)
WO (1) WO2014078645A1 (es)
ZA (2) ZA201504294B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
KR20150085053A (ko) 2012-11-16 2015-07-22 칼리테라 바이오사이언시즈 인코포레이티드 헤테로사이클릭 글루타미나아제 억제제
WO2014089048A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
BR112016015706A8 (pt) 2014-01-06 2020-06-09 Rhizen Pharmaceuticals S A compound, use of it and pharmaceutical composition
KR20160149256A (ko) 2014-04-30 2016-12-27 화이자 인코포레이티드 시클로알킬-결합된 디헤테로사이클 유도체
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9687485B2 (en) 2014-06-13 2017-06-27 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US20160002248A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
SI3164394T1 (sl) 2014-07-03 2020-08-31 Board Of Regents, The University Of Texas System GLS1 inhibitors for the treatment of disease
EP3164195A4 (en) * 2014-07-03 2018-01-17 Board of Regents, The University of Texas System Glutaminase inhibitor therapy
WO2016007647A1 (en) * 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
CN106999490A (zh) * 2014-08-07 2017-08-01 卡利泰拉生物科技公司 晶体形式的谷氨酰胺酶抑制剂
BR112017020780A2 (pt) * 2015-03-30 2018-06-26 Calithera Biosciences Inc Glutaminase inhibitor administration methods
CA2981762A1 (en) 2015-04-06 2016-10-13 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
AU2016287661B2 (en) 2015-06-30 2020-07-16 Board Of Regents, University Of Texas System GLS1 inhibitors for treating disease
SG11201802830QA (en) 2015-10-05 2018-05-30 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors and immuno-oncology agents
TW201733587A (zh) * 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201730188A (zh) * 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
KR20180095677A (ko) 2015-12-22 2018-08-27 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 (r)-1-(4-(6-(2-(4-(3,3-디플루오로시클로부톡시)-6-메틸피리딘-2-일)아세트아미도)피리다진-3-일)-2-플루오로부틸)-n-메틸-1h-1,2,3-트리아졸-4-카르복사미드의 염 형태 및 다형체
CA3034890A1 (en) * 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN109982703A (zh) * 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
WO2018039442A1 (en) * 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Treatment of cancer with inhibitors of glutaminase
JP2020523369A (ja) * 2017-06-13 2020-08-06 メッドシャイン ディスカバリー インコーポレイテッド Gls1阻害剤としての化合物
US10722487B2 (en) 2017-10-18 2020-07-28 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
EP1747282B1 (en) 2004-04-15 2011-06-08 University of Florida Research Foundation, Inc. Map-2 proteolytic breakdown products as diagnostic biomarkers for neural injury
WO2011143160A2 (en) * 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
EP2782570B1 (en) * 2011-11-21 2019-09-18 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
KR20150085053A (ko) 2012-11-16 2015-07-22 칼리테라 바이오사이언시즈 인코포레이티드 헤테로사이클릭 글루타미나아제 억제제
EP2922832B1 (en) 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2014089048A1 (en) 2012-12-03 2014-06-12 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
US20150258082A1 (en) 2014-03-14 2015-09-17 Francesco Parlati Combination therapy with glutaminase inhibitors
US9687485B2 (en) 2014-06-13 2017-06-27 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN106999490A (zh) 2014-08-07 2017-08-01 卡利泰拉生物科技公司 晶体形式的谷氨酰胺酶抑制剂
BR112017020780A2 (pt) 2015-03-30 2018-06-26 Calithera Biosciences Inc Glutaminase inhibitor administration methods
CA2981762A1 (en) 2015-04-06 2016-10-13 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
SG11201802830QA (en) 2015-10-05 2018-05-30 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors and immuno-oncology agents
CA3034890A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
EP3592354A1 (en) 2017-03-10 2020-01-15 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors

Also Published As

Publication number Publication date
EP2920168A4 (en) 2016-04-20
ZA201504294B (en) 2018-12-19
EP2920168A1 (en) 2015-09-23
CA2891667A1 (en) 2014-05-22
IL238787D0 (en) 2015-06-30
JP6275153B2 (ja) 2018-02-07
ZA201606590B (en) 2019-04-24
CN105051041B (zh) 2018-03-30
SG11201503720SA (en) 2015-06-29
CN105051041A (zh) 2015-11-11
JP2016505526A (ja) 2016-02-25
EA201590941A1 (ru) 2016-02-29
EA029707B1 (ru) 2018-05-31
WO2014078645A1 (en) 2014-05-22
AU2013344560B2 (en) 2017-09-14
US20140194421A1 (en) 2014-07-10
BR112015010955A2 (pt) 2017-07-11
KR20150085053A (ko) 2015-07-22
US10793535B2 (en) 2020-10-06
HK1215023A1 (zh) 2016-08-12

Similar Documents

Publication Publication Date Title
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12017500296A1 (en) Anti-tigit antibodies
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
MX2017017097A (es) QUIRAL DIARYLIC MACROCYCLES AS MODULATORS OF KINASE PROTEINS.
PH12015501552A1 (en) Androgen receptor modulator and uses thereof
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2018000048A (es) HPK1 INHIBITORS AND METHODS OF USE OF THE SAME.
IL237761A (en) Pyrrolo[3.2-d] pyrimidine derivatives for the treatment of viral infections and other diseases
PH12015502615B1 (en) Chemical compounds
PH12017501419A1 (en) Therapeutically active compounds and their method of use
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
PH12014501876A1 (en) Dll3 modulators and methods of use
MX2015017532A (es) METHODS TO MODULATE THE ACTIVITY OF THE CHEMICAL FIBROSIS TRANSMEMBRANE REGULATOR.
AU2015237050A8 (en) Quinoline derivatives as SMO inhibitors
NZ709769A (en) 2-aminopyrimidine derivatives for the treatment of viral infections
TN2015000396A1 (en) Antibody drug conjugates
PH12015500825A1 (en) Substituted benzene compounds
PH12014501738B1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX2017004691A (es) CD73 LOCK.
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
NZ711946A (en) Newcastle disease viruses and uses thereof